HALLE (SAALE), Germany, May 7, 2021 /PRNewswire/ -- OntoChem GmbH, a German Life Science IT company, announced today that it has assigned its drug discovery technologies and assets, including its drug discovery collaboration with Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, to the newly formed MolGenie GmbH, a biotech company focusing on drug discovery and development.
Anixa Biosciences and OntoChem are set to enter the next stage of developing their potential anti-viral therapy for Covid-19 on obtaining results from a Proof of Concept (POC) animal study.
SAN JOSE, Calif., Aug. 13, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it and partner OntoChem have identified additional candidates through their in silico screening study. In addition to four compounds that target an endoribonuclease (also known as Non-Structural Protein-15, or NSP-15) and one additional core compound that targets the main protease (Mpro) of the virus, Anixa and OntoChem have identified 26 additional compounds targeting Mpro.
SAN JOSE, Calif., July 6, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it and partner OntoChem have completed the initial in silico screening process of their drug discovery program and have identified an additional specific compound, as well as multiple analogs, that could function as inhibitors of the main protease (Mpro) of the virus. As previously announced, Anixa and OntoChem have identified four compounds that could disrupt the function of a viral enzyme called an endoribonuclease (also known as Non-Structural Protein-15, or NSP-15).
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, today announced that the Company, together with partner OntoChem GmbH, has synthesized four potential Covid-19 compounds that will advance to biological assay testing. Anixa and OntoChem announced their partnership on April 20, 2020 (https://ir.anixa.com/press-releases/detail/947/) and announced discovery of its first potential Covid-19 candidate two weeks later on May 4, 2020.
SAN JOSE, Calif., April 5, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that based on Proof of Concept (POC) animal study results, it will progress to the next stage of development of its potential anti-viral therapy for Covid-19.
Anixa Biosciences, Inc., a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced that based on Proof of Concept (POC) animal study results, it will progress to the next stage of development of its potential anti-viral therapy for Covid-19.